Alzheimer’s Disease Treatment

Jul 22, 2025

Sarepta Therapeutics Pauses ELEVIDYS Shipments in U.S. After FDA Intervention Over Patient Deaths Sarepta Therapeutics, Inc. has voluntarily and temporarily paused all shipments of ELEVIDYS (delandistrogene moxeparvovec) in the U.S., effective July 22, 2025, following engagement with the FDA on safety labeling u...

Feb 26, 2025

Alzheimer’s disease remains one of the most complex and devastating neurodegenerative disorders, affecting millions worldwide and placing an immense burden on patients, caregivers, and healthcare systems. Characterized by progressive cognitive decline, memory loss, and functional impairment, Alzheimer’s disease cur...

Feb 12, 2025

Alzheimer’s disease is a devastating neurodegenerative disorder that affects millions worldwide, progressively impairing memory, cognitive function, and independence. Despite extensive research, current Alzheimer’s disease drugs provide only limited relief, and there remains no cure. With the number of cases projec...

Feb 12, 2025

Alzheimer’s, the most common type of dementia, particularly with an increasing geriatric population, presents a major global crisis. The disease mostly occurs in sexagenarians, but it may manifest in quadragenarians. It is one of the most prevalent neurodegenerative disorders with a multifactorial pathogenesis. It ...

Feb 12, 2025

Alzheimer’s disease has become one of the most pressing global health challenges, with its prevalence rising dramatically over the past few years. As the aging population grows, so does the burden of this neurodegenerative disorder, placing immense strain on healthcare systems worldwide. The Alzheimer's drug market...

Feb 12, 2025

Alzheimer’s disease is the most common type of dementia, accounting for more than 60% of all cases, and is characterized by a gradual decline in cognitive and functional abilities. It represents a global health crisis that is increasing with the increasing geriatric population. It represents a global health crisis ...